Augmentin :: Multiple pharmacies comparison.

PHILADELPHIA — GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration has issued an approvable letter for its topical antibacterial, Altabax (retapamulin ointment), 1%, for the treatment of secondarily-infected traumatic lesions (SITL). SITL is a type of skin and skin structure infection most commonly caused by Staphylococcus aureus and Streptococcus pyogenes.
In the letter to GSK, the FDA requested additional information to complete its asses…

MRSA Update
Skin and soft tissue infections due to resistant forms of the Staph. bacteria have increased dramatically in recent years. For those of us who take care of kids in hospitals, these conditions have reached near-epidemic proportions.
Articles have appeared in the lay press about the subject, as more and more of the population experiences infections. This, and th…

Business Editors and Medical/Health Writers
JERUSALEM, Israel–(BUSINESS WIRE)–March 13, 2002
Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA) announced today that a federal judge has ruled in its favor, invalidating three GlaxoSmithKline patents, otherwise due to expire in 2017, covering the antibiotic Augmentin(R).
The ruling fo…

Business Editors/Health/Medical Writers
LYON, France–(BUSINESS WIRE)–Oct. 20, 2003
Flamel Technologies S.A. (Nasdaq:FLML) today announced that the License Agreement with Beecham Pharmaceuticals (Pte) Limited for the sachet formulation of augmentin, incorporating Flamel’s Micropump(R) technology, will be terminated as of J…

Feb. 1–NEW DELHI — Gurgaon-based pharmaceutical major Ranbaxy Labs today announced that RLL has received approval from the US Food and Drug Administration to market Amoxicillin and Clavulanate Potassium for Oral Suspension. The Division of Bioequivalence has determined the Ranbaxy formulation to be…

NEW YORK — Novartis expects to boost profits after winning a patent case over generic forms of GlaxoSmithKline’s (GSK’s) Augmentin. Novartis’ Geneva Pharmaceuticals division debuted its version of the antibiotic in July 2002, but Novartis opted not to book profits on sales in case it lost the patent case on appeal.

Novartis has held back book profits for the drug from the middle of 2002 to March …

Doctors, parents, and pharmaceutical companies all like to believe that giving antibiotics to children with ear infections really makes a difference. A recent Finnish study finds that Augmentin (a combination of amoxicillin and clavulanate) does make a difference.
Sixty six children, ages 6-months-to 6-years-old, with tympanostomy tubes (tubes in their ear drums) met the study criteria. Each had pussy fluid (otorrhea) coming through at least one ear tube–an indication of midd…

GLAXOSMITHKLINE yesterday revised down its growth forecasts for the next two years, after a rival drug maker launched a cheap version of its biggest-selling antibiotic.
Novartis, the Swiss giant, has launched a generic copy of Augmentin, a multi-purpose…